The efficacy of molecularly targeted anti-cancer therapies may be limited by the presence of
co-occurring mutations within a tumor–. Conversely, these alterations may confer collateral�…

The treatment approach to advanced, ALK-positive non-small cell lung cancer (NSCLC)
utilizing sequential ALK tyrosine kinase inhibitors (TKIs) represents a paradigm of precision�…

Efficient multiple-or single-wavelength anomalous dispersion (MAD/SAD) techniques that
use tunable X-ray sources at third-generation synchrotrons exploit the anomalous scattering�…

Summary Two-dimensional (2D) culture of tumor cells fails to recapitulate some important
aspects of cellular organization seen in in vivo experiments. In addition, cell cultures�…

Despite initially responding, EGFR-mutant non-small cell lung cancer (NSCLC) patients
treated with EGFR tyrosine kinase inhibitors (TKIs) invariably acquire drug resistance. A�…

Discrete, organic anions provide an attractive alternative for the synthesis of molecular
superconductors. We have previously prepared the first completely organic superconductor�…

7555 Background: Recent efforts in targeting the PD-1/PD-L1 pathway in solid tumors have
resulted in durable responses in early phase clinical trials. Additionally, it has been reported�…

This article was originally published under a standard Springer Nature license (� The
Author (s), under exclusive licence to Springer Nature America, Inc.); it is now available as�…

Methods: EML4-ALK fusion cell lines were established from NSCLC patients: MGH026-1,
MGH048-1, and MGH064-1 (treatment-na�ve); MGH045-1 (L1196M post-crizotinib);�…

We, the authors, are retracting this Letter owing to anomalies in Figs. 2j, 3a and 3d. We and
the Nature editors reviewed the data and found that these anomalies were present in the�…